Your session is about to expire
← Back to Search
Diagnostic Test
Intensive Screening with FDG PET/CT for Occult Cancer After Stroke (INCOGNITO Trial)
N/A
Recruiting
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up over 24 months
Awards & highlights
INCOGNITO Trial Summary
This trial assesses if PET/CT scans can find cancer in patients with stroke when regular tests cannot.
Who is the study for?
This trial is for adults over 18 who've had a cryptogenic ischemic stroke, as defined by American Heart Association guidelines, and are able to consent. They must be seen at the Ottawa Hospital Stroke Prevention Clinic or Neurovascular Unit within 3 months of their stroke. Pregnant individuals or those with active/previous cancers (except certain skin cancers) can't participate.Check my eligibility
What is being tested?
The INCOGNITO Pilot Trial is testing if adding FDG PET/CT scans to usual care helps find more hidden cancers in patients who have had an unexplained stroke compared to just usual care. It's a small-scale study designed to see if a larger one would be feasible.See study design
What are the potential side effects?
Since this trial involves FDG PET/CT scans, potential side effects may include discomfort from lying still during the scan and exposure to low levels of radiation. Usual care typically doesn't involve additional side effects.
INCOGNITO Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ over 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~over 24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Participant Recruitment
Secondary outcome measures
Adherence Rate
Consent Rate
Eligibility Rate
+2 moreOther outcome measures
Reasons for participation
Screening time frame
Usual care cancer screening strategies
INCOGNITO Trial Design
2Treatment groups
Experimental Treatment
Group I: Usual CareExperimental Treatment1 Intervention
Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)
Group II: Intensive Cancer ScreeningExperimental Treatment1 Intervention
Usual care plus PDG PET/CT
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FDG PET/CT
2014
N/A
~170
Usual Care
1990
Completed Phase 4
~7700
Find a Location
Who is running the clinical trial?
Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,785,449 Total Patients Enrolled
Canadian Stroke Consortium (CSC)OTHER
3 Previous Clinical Trials
2,414 Total Patients Enrolled
Brain CanadaOTHER
18 Previous Clinical Trials
5,993 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are patients currently being enrolled in this clinical investigation?
"Affirmative, according to clinicaltrials.gov this trial is actively recruiting patients; it was initially posted on September 1st 2023 before its most recent update of October 30th 2023. The research project aims to enrol 45 participants at a single medical facility."
Answered by AI
To what extent is the participant pool for this clinical examination expanding?
"Affirmative. The data hosted on clinicaltrials.gov reports that the trial is currently accepting applicants and was first posted on September 1st 2023, with a recent update occurring October 30th of the same year. 45 participants across one location are desired for this study's completion."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger